NaQuinate is under clinical development by Haoma Medica and currently in Phase I for Osteoporosis. According to GlobalData, Phase I drugs for Osteoporosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NaQuinate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NaQuinate overview
NaQuinate is under development for the treatment of osteoporosis and osteopenia. It is administered orally. It is a small molecule naturally occurring metabolite of vitamin K with low toxicity and high oral bioavailability.
Haoma Medica overview
Haoma Medica is a biotechnology company that develops drugs for the treatment of osteopenia, osteoporosis, and blood clotting management. The company’s osteoporosis and osteopenia drugs include NaQuinate commercially known as Osteopura developed for low-dose oral administration. Haoma Medica’s product, Osteopura is used for the treatment and prevention of long bone fractures and provides anabolic characteristics. The company’s products are in the preclinical stage of clinical trials. It has been granted patent rights for its product in the UK, the US, China, Japan, India, Australia, Hong Kong, Israel, and Russia. Haoma Medica is headquartered in London, Greater London, the UK.
For a complete picture of NaQuinate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
